Myoventive is a precision-cardiology therapeutics company developing next-generation RNA-based medicines to transform the treatment of genetic heart disease. Bringing together a seasoned leadership team with deep experience in RNA biology, antibody engineering, and drug development.
Myoventive is backed by venBio, Perceptive Xontogeny Funds, with financing expected to support advancement of a lead program toward IND submission.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.